SCHEMBL29796828

SCHEMBL29796828

CC(C)(C)OC(=O)N[C@H]1CSc2cc(F)c(-c3noc(C(C)(C)C)n3)cc2N(Cc2ccc(Cl)cc2)C1=O

nearest known ligand 0.38

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 8/20 0.38
▸ HDAC1 Q13547 6/20 0.38
▸ HDAC8 Q9BY41 6/20 0.38
▸ BDKRB1 P46663 4/20 0.36
▸ HDAC5 Q9UQL6 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HDAC4 P56524 1/20 0.34
▸ P2RX3 P56373 3/20 0.34
▸ CNR1 P21554 1/20 0.33
▸ CNR2 P34972 1/20 0.33
▸ RIPK1 Q13546 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26961865 1.00 HDAC6 (0.38) HDAC6HDAC1HDAC8BDKRB1HDAC5
SCHEMBL26962186 0.93 HDAC6 (0.36) HDAC6HDAC1HDAC8BDKRB1HDAC5
SCHEMBL32670508 0.93 HDAC6 (0.38) HDAC6HDAC1HDAC8BDKRB1HDAC5
SCHEMBL26962242 0.92 HDAC6 (0.37) HDAC6HDAC1HDAC8BDKRB1HDAC5
SCHEMBL26961676 0.90 HDAC6 (0.37) HDAC6HDAC1HDAC8BDKRB1HDAC5
SCHEMBL29796770 0.90 HDAC6 (0.37) HDAC6HDAC1HDAC8BDKRB1HDAC5
SCHEMBL26962114 0.89 BDKRB1 (0.34) HDAC6HDAC1HDAC8BDKRB1POLB
SCHEMBL26962822 0.88 BDKRB1 (0.36) HDAC6HDAC1HDAC8BDKRB1POLB
SCHEMBL29796940 0.88 HDAC6 (0.35) HDAC6HDAC1HDAC8HDAC5HDAC4
SCHEMBL26961758 0.88 HDAC6 (0.35) HDAC6HDAC1HDAC8HDAC5HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4291558-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2023-12-20 — — EP disclosed
WO-2022171745-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2022-08-18 — — WO disclosed
Send feedback